

Hao-Peng Sun

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4841591/publications.pdf>

Version: 2024-02-01

156
papers

4,257
citations

126907

33
h-index

155660

55
g-index

159
all docs

159
docs citations

159
times ranked

5799
citing authors

#	ARTICLE	IF	CITATIONS
1	The recent progress of isoxazole in medicinal chemistry. <i>Bioorganic and Medicinal Chemistry</i> , 2018, 26, 3065-3075.	3.0	233
2	Recent progress in the identification of selective butyrylcholinesterase inhibitors for Alzheimer's disease. <i>European Journal of Medicinal Chemistry</i> , 2017, 132, 294-309.	5.5	229
3	Degradation of proteins by PROTACs and other strategies. <i>Acta Pharmaceutica Sinica B</i> , 2020, 10, 207-238.	12.0	196
4	Discovery of Potent Keap1-Nrf2 Protein-Protein Interaction Inhibitor Based on Molecular Binding Determinants Analysis. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 2736-2745.	6.4	193
5	Rational Design of Multitarget-Directed Ligands: Strategies and Emerging Paradigms. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 8881-8914.	6.4	164
6	Donepezil-based multi-functional cholinesterase inhibitors for treatment of Alzheimer's disease. <i>European Journal of Medicinal Chemistry</i> , 2018, 158, 463-477.	5.5	136
7	NRF2 promotes breast cancer cell proliferation and metastasis by increasing RhoA/ROCK pathway signal transduction. <i>Oncotarget</i> , 2016, 7, 73593-73606.	1.8	101
8	Structure-Activity and Structure-Property Relationship and Exploratory in Vivo Evaluation of the Nanomolar Keap1-Nrf2 Protein-Protein Interaction Inhibitor. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 6410-6421.	6.4	76
9	Dual GSK-3 β /AChE Inhibitors as a New Strategy for Multitargeting Anti-Alzheimer's Disease Drug Discovery. <i>ACS Medicinal Chemistry Letters</i> , 2018, 9, 171-176.	2.8	76
10	Strategies for Structural Modification of Small Molecules to Improve Blood-Brain Barrier Penetration: A Recent Perspective. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 13152-13173.	6.4	69
11	Peptide-based and small synthetic molecule inhibitors on PD-1/PD-L1 pathway: A new choice for immunotherapy?. <i>European Journal of Medicinal Chemistry</i> , 2019, 161, 378-398.	5.5	66
12	Garcinia Xanthones as Orally Active Antitumor Agents. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 276-292.	6.4	55
13	Novel protein-protein interaction inhibitor of Nrf2-Keap1 discovered by structure-based virtual screening. <i>MedChemComm</i> , 2014, 5, 93-98.	3.4	55
14	Discovery of new acetylcholinesterase and butyrylcholinesterase inhibitors through structure-based virtual screening. <i>RSC Advances</i> , 2017, 7, 3429-3438.	3.6	55
15	Synthesis, pharmacology and molecular docking on multifunctional tacrine-ferulic acid hybrids as cholinesterase inhibitors against Alzheimer's disease. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2018, 33, 496-506.	5.2	52
16	CDK8 as a therapeutic target for cancers and recent developments in discovery of CDK8 inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2019, 164, 77-91.	5.5	49
17	Discovery and Modification of in Vivo Active Nrf2 Activators with 1,2,4-Oxadiazole Core: Hits Identification and Structure-Activity Relationship Study. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 5419-5436.	6.4	48
18	Discovery and Biological Evaluation of a Novel Highly Potent Selective Butyrylcholinesterase Inhibitor. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 10030-10044.	6.4	48

#	ARTICLE	IF	CITATIONS
19	Overview of AKR1C3: Inhibitor Achievements and Disease Insights. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 11305-11329.	6.4	47
20	2-Substituted 3-methylnaphtho[1,2-b]furan-4,5-diones as novel L-shaped ortho-quinone substrates for NAD(P)H:quinone oxidoreductase (NQO1). <i>European Journal of Medicinal Chemistry</i> , 2014, 82, 56-67.	5.5	46
21	Recent research progress of <i>Uncaria</i> spp. based on alkaloids: phytochemistry, pharmacology and structural chemistry. <i>European Journal of Medicinal Chemistry</i> , 2021, 210, 112960.	5.5	45
22	Structure and therapeutic uses of butyrylcholinesterase: Application in detoxification, Alzheimer's disease, and fat metabolism. <i>Medicinal Research Reviews</i> , 2021, 41, 858-901.	10.5	45
23	Insight into the Intermolecular Recognition Mechanism between Keap1 and IKK β Combining Homology Modelling, Protein-Protein Docking, Molecular Dynamics Simulations and Virtual Alanine Mutation. <i>PLoS ONE</i> , 2013, 8, e75076.	2.5	42
24	3-Aroylmethylene-2,3,6,7-tetrahydro-1 <i>H</i> -pyrazino[2,1- <i>a</i>]isoquinolin-4(1 <i>H</i>)-ones as Potent Nrf2/ARE Inducers in Human Cancer Cells and AOM-DSS Treated Mice. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 7925-7938.	6.4	40
25	Structure-based design and synthesis of small molecular inhibitors disturbing the interaction of MLL1-WDR5. <i>European Journal of Medicinal Chemistry</i> , 2016, 118, 1-8.	5.5	38
26	Small molecule modulators targeting protein kinase CK1 and CK2. <i>European Journal of Medicinal Chemistry</i> , 2019, 181, 111581.	5.5	38
27	Highly Potent and Selective Butyrylcholinesterase Inhibitors for Cognitive Improvement and Neuroprotection. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 6856-6876.	6.4	38
28	Small molecule PROTACs in targeted therapy: An emerging strategy to induce protein degradation. <i>European Journal of Medicinal Chemistry</i> , 2019, 174, 159-180.	5.5	37
29	STING, a promising target for small molecular immune modulator: A review. <i>European Journal of Medicinal Chemistry</i> , 2021, 211, 113113.	5.5	37
30	Key Role of Nuclear Factor- κ B in the Cellular Pharmacokinetics of Adriamycin in MCF-7/Adr Cells: The Potential Mechanism for Synergy with 20(<i>S</i>)-Ginsenoside Rh2. <i>Drug Metabolism and Disposition</i> , 2012, 40, 1900-1908.	3.3	36
31	Identification and optimization of novel Hsp90 inhibitors with tetrahydropyrido[4,3- <i>d</i>]pyrimidines core through shape-based screening. <i>European Journal of Medicinal Chemistry</i> , 2014, 79, 399-412.	5.5	36
32	Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016). <i>Expert Opinion on Therapeutic Patents</i> , 2017, 27, 763-785.	5.0	36
33	Current Development of ROS-Modulating Agents as Novel Antitumor Therapy. <i>Current Cancer Drug Targets</i> , 2017, 17, 122-136.	1.6	36
34	Synthesis and evaluation of (Δ^{\pm})-dunnione and its ortho-quinone analogues as substrates for NAD(P)H:quinone oxidoreductase 1 (NQO1). <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 1244-1248.	2.2	35
35	Design, synthesis, in vitro and in vivo evaluation of tacrine-cinnamic acid hybrids as multi-target acetyl- and butyrylcholinesterase inhibitors against Alzheimer's disease. <i>RSC Advances</i> , 2017, 7, 33851-33867.	3.6	35
36	The Development of Pharmacophore Modeling: Generation and Recent Applications in Drug Discovery. <i>Current Pharmaceutical Design</i> , 2018, 24, 3424-3439.	1.9	35

#	ARTICLE	IF	CITATIONS
37	Predicting the potency of hERG K ⁺ channel inhibition by combining 3D-QSAR pharmacophore and 2D-QSAR models. <i>Journal of Molecular Modeling</i> , 2012, 18, 1023-1036.	1.8	34
38	Design, synthesis, biological evaluation, and molecular modeling studies of quinoline-ferulic acid hybrids as cholinesterase inhibitors. <i>Bioorganic Chemistry</i> , 2019, 93, 103310.	4.1	33
39	Synthesis and bioevaluation of new tacrine-cinnamic acid hybrids as cholinesterase inhibitors against Alzheimer's disease. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2018, 33, 290-302.	5.2	31
40	Bioactivity-based analysis and chemical characterization of hypoglycemic and antioxidant components from <i>Artemisia argyi</i> . <i>Bioorganic Chemistry</i> , 2019, 92, 103268.	4.1	31
41	Therapeutic Agents in Alzheimer's Disease Through a Multi-target directed Ligands Strategy: Recent Progress Based on Tacrine Core. <i>Current Topics in Medicinal Chemistry</i> , 2017, 17, 3000-3016.	2.1	31
42	Targeted degradation of anaplastic lymphoma kinase by gold nanoparticle-based multi-headed proteolysis targeting chimeras. <i>Colloids and Surfaces B: Biointerfaces</i> , 2020, 188, 110795.	5.0	30
43	PROTACs suppression of GSK-3 β , a crucial kinase in neurodegenerative diseases. <i>European Journal of Medicinal Chemistry</i> , 2021, 210, 112949.	5.5	29
44	Synthesis and bioevaluation of a series of β -pyrone derivatives as potent activators of Nrf2/ARE pathway (part I). <i>European Journal of Medicinal Chemistry</i> , 2013, 66, 364-371.	5.5	27
45	Investigation of multi-target-directed ligands (MTDLs) with butyrylcholinesterase (BuChE) and indoleamine 2,3-dioxygenase 1 (IDO1) inhibition: The design, synthesis of miconazole analogues targeting Alzheimer's disease. <i>Bioorganic and Medicinal Chemistry</i> , 2018, 26, 1665-1674.	3.0	27
46	Reasonably activating Nrf2: A long-term, effective and controllable strategy for neurodegenerative diseases. <i>European Journal of Medicinal Chemistry</i> , 2020, 185, 111862.	5.5	27
47	Therapeutic strategies of glioblastoma (GBM): The current advances in the molecular targets and bioactive small molecule compounds. <i>Acta Pharmaceutica Sinica B</i> , 2022, 12, 1781-1804.	12.0	27
48	p62/SQSTM1, a Central but Unexploited Target: Advances in Its Physiological/Pathogenic Functions and Small Molecular Modulators. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 10135-10157.	6.4	26
49	Investigation of the intermolecular recognition mechanism between the E3 ubiquitin ligase Keap1 and substrate based on multiple substrates analysis. <i>Journal of Computer-Aided Molecular Design</i> , 2014, 28, 1233-1245.	2.9	25
50	Novel naphtho[2,1-d]oxazole-4,5-diones as NQO1 substrates with improved aqueous solubility: Design, synthesis, and in vivo antitumor evaluation. <i>Bioorganic and Medicinal Chemistry</i> , 2016, 24, 1006-1013.	3.0	25
51	Design of Small Molecule Autophagy Modulators: A Promising Druggable Strategy. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 4656-4687.	6.4	25
52	Inhibition of Histone Deacetylase 6 (HDAC6) as a therapeutic strategy for Alzheimer's disease: A review (2010-2020). <i>European Journal of Medicinal Chemistry</i> , 2021, 226, 113874.	5.5	25
53	Discovery of new acetylcholinesterase inhibitors with small core structures through shape-based virtual screening. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 3442-3446.	2.2	24
54	Design, synthesis and evaluation of novel bivalent β -carboline derivatives as multifunctional agents for the treatment of Alzheimer's disease. <i>Bioorganic and Medicinal Chemistry</i> , 2018, 26, 3812-3824.	3.0	24

#	ARTICLE	IF	CITATIONS
55	Expansion of the scaffold diversity for the development of highly selective butyrylcholinesterase (BChE) inhibitors: Discovery of new hits through the pharmacophore model generation, virtual screening and molecular dynamics simulation. <i>Bioorganic Chemistry</i> , 2019, 85, 117-127.	4.1	24
56	Design and bio-evaluation of indole derivatives as potent Kv1.5 inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2013, 21, 6466-6476.	3.0	23
57	Effective Screening Strategy Using Ensembled Pharmacophore Models Combined with Cascade Docking: Application to p53-MDM2 Interaction Inhibitors. <i>Journal of Chemical Information and Modeling</i> , 2013, 53, 2715-2729.	5.4	23
58	Recent Advances in the Discovery of HIF-1 α -p300/CBP Inhibitors as Anti-Cancer Agents. <i>Mini-Reviews in Medicinal Chemistry</i> , 2018, 18, 296-309.	2.4	23
59	Synthesis and evaluation of novel aza-caged Garcinia xanthonoids. <i>Organic and Biomolecular Chemistry</i> , 2012, 10, 3288.	2.8	22
60	A sensitive colorimetric strategy for monitoring cerebral β -amyloid peptides in AD based on dual-functionalized gold nanoplasmonic particles. <i>Chemical Communications</i> , 2015, 51, 8880-8883.	4.1	22
61	Affinity-Based Fluorescence Polarization Assay for High-Throughput Screening of Prolyl Hydroxylase 2 Inhibitors. <i>ACS Medicinal Chemistry Letters</i> , 2015, 6, 1236-1240.	2.8	22
62	Small molecule KDM4s inhibitors as anti-cancer agents. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2018, 33, 777-793.	5.2	22
63	Influence of c-Src on hypoxic resistance to paclitaxel in human ovarian cancer cells and reversal of FV-429. <i>Cell Death and Disease</i> , 2018, 8, e3178-e3178.	6.3	22
64	G9a - An Appealing Antineoplastic Target. <i>Current Cancer Drug Targets</i> , 2017, 17, 555-568.	1.6	22
65	Discovery of Resorcinol-Based Polycyclic Structures as Tyrosinase Inhibitors for Treatment of Parkinson's Disease. <i>ACS Chemical Neuroscience</i> , 2022, 13, 81-96.	3.5	22
66	Studies on gambogic acid (IV): Exploring structure-activity relationship with $\text{I}\kappa\text{B}$ kinase-beta (IKK β). <i>European Journal of Medicinal Chemistry</i> , 2012, 51, 110-123.	5.5	21
67	Novel natural-product-like caged xanthonoids with improved druglike properties and in vivo antitumor potency. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 2584-2588.	2.2	21
68	Chemical Constituents of the Seed Cake of <i>Camellia oleifera</i> and Their Antioxidant and Antimelanogenic Activities. <i>Chemistry and Biodiversity</i> , 2018, 15, e1800137.	2.1	21
69	Small molecular Nrf2 inhibitors as chemosensitizers for cancer therapy. <i>Future Medicinal Chemistry</i> , 2020, 12, 243-267.	2.3	21
70	Recent Advances in the Structure-Based and Ligand-Based Design of IKK β Inhibitors as Anti-inflammation and Anti-cancer Agents. <i>Current Medicinal Chemistry</i> , 2014, 21, 3893-3917.	2.4	21
71	Novel N-hydroxyfurylacrylamide-based histone deacetylase (HDAC) inhibitors with branched CAP group (Part 2). <i>Bioorganic and Medicinal Chemistry</i> , 2013, 21, 5339-5354.	3.0	20
72	Discovery and identification of Cdc37-derived peptides targeting the Hsp90 α -Cdc37 protein-protein interaction. <i>RSC Advances</i> , 2015, 5, 96138-96145.	3.6	20

#	ARTICLE	IF	CITATIONS
73	Palladium(II)-Catalyzed C-H Bond Activation/C-C Coupling/Intramolecular Tsuji-Trost Reaction Cascade: Facile Access to 2-H-Pyranonaphthoquinones. <i>Organic Letters</i> , 2015, 17, 3410-3413.	4.6	20
74	Anti-angiogenic and anticancer effects of baicalein derivatives based on transgenic zebrafish model. <i>Bioorganic and Medicinal Chemistry</i> , 2018, 26, 4481-4492.	3.0	20
75	Synthesis, cytotoxicity and topoisomerase II inhibitory activity of lomefloxacin derivatives. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 2974-2978.	2.2	19
76	Gamma secretase inhibitors: a patent review (2013 - 2015). <i>Expert Opinion on Therapeutic Patents</i> , 2017, 27, 851-866.	5.0	19
77	Design, synthesis, <i>in vitro</i> and <i>in vivo</i> evaluation of benzylpiperidine-linked 1,3-dimethylbenzimidazolinones as cholinesterase inhibitors against Alzheimer's disease. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2020, 35, 330-343.	5.2	19
78	Discovery and Design of Tricyclic Scaffolds as Protein Kinase CK2 (CK2) Inhibitors through a Combination of Shape-Based Virtual Screening and Structure-Based Molecular Modification. <i>Journal of Chemical Information and Modeling</i> , 2013, 53, 2093-2102.	5.4	18
79	Novel 5-carboxy-8-HQ based histone demethylase JMJD2A inhibitors: Introduction of an additional carboxyl group at the C-2 position of quinoline. <i>European Journal of Medicinal Chemistry</i> , 2015, 105, 145-155.	5.5	18
80	Identification of 4-aminoquinoline core for the design of new cholinesterase inhibitors. <i>PeerJ</i> , 2016, 4, e2140.	2.0	18
81	<i>tert</i> -butylphenylphosphinoyl acetyl as a Remote Directing Group for the Highly Stereoselective Synthesis of <i>trans</i> -Glycosides. <i>Chinese Journal of Chemistry</i> , 2022, 40, 443-452.	4.9	18
82	Identification, Design and Bio-Evaluation of Novel Hsp90 Inhibitors by Ligand-Based Virtual Screening. <i>PLoS ONE</i> , 2013, 8, e59315.	2.5	17
83	Lewis acid mediated highly regioselective intramolecular cyclization for the synthesis of <i>trans</i> -lapachone. <i>Tetrahedron Letters</i> , 2014, 55, 1475-1478.	1.4	17
84	Discovery of new scaffolds from approved drugs as acetylcholinesterase inhibitors. <i>RSC Advances</i> , 2015, 5, 90288-90294.	3.6	17
85	Therapeutic potential of phosphodiesterase inhibitors for cognitive amelioration in Alzheimer's disease. <i>European Journal of Medicinal Chemistry</i> , 2022, 232, 114170.	5.5	17
86	Discovery of 1-aryloxyethyl piperazine derivatives as Kv1.5 potassium channel inhibitors (part I). <i>European Journal of Medicinal Chemistry</i> , 2014, 81, 89-94.	5.5	16
87	Discovery of novel covalent proteasome inhibitors through a combination of pharmacophore screening, covalent docking, and molecular dynamics simulations. <i>Journal of Molecular Modeling</i> , 2014, 20, 2515.	1.8	15
88	Microwave-assisted transition-metal-free intramolecular Ullmann-type O-arylation in water for the synthesis of xanthenes and azaxanthenes. <i>Tetrahedron Letters</i> , 2014, 55, 4883-4887.	1.4	15
89	Rational design and biological evaluation of a new class of thiazolopyridyl tetrahydroacridines as cholinesterase and GSK-3 dual inhibitors for Alzheimer's disease. <i>European Journal of Medicinal Chemistry</i> , 2020, 207, 112751.	5.5	15
90	Design, synthesis and biological evaluation of novel carboline-cinnamic acid hybrids as multifunctional agents for treatment of Alzheimer's disease. <i>Bioorganic Chemistry</i> , 2020, 99, 103844.	4.1	15

#	ARTICLE	IF	CITATIONS
91	Synthesis and Evaluation of Gambogic Acid Derivatives as Antitumor Agents. Part III. Chemistry and Biodiversity, 2013, 10, 73-85.	2.1	14
92	Discovery of potent glycogen synthase kinase 3/cholinesterase inhibitors with neuroprotection as potential therapeutic agent for Alzheimer's disease. Bioorganic and Medicinal Chemistry, 2021, 30, 115940.	3.0	14
93	Combination of pharmacophore model development and binding mode analyses: Identification of ligand features essential for I β B kinase-beta (IKK β) inhibitors and virtual screening based on it. European Journal of Medicinal Chemistry, 2011, 46, 3942-3952.	5.5	13
94	Total synthesis of aldehyde-containing Garcinia natural products isomorellin and gaudichaudione A. Tetrahedron, 2011, 67, 4774-4779.	1.9	13
95	Discovery and optimization of new benzofuran derivatives against p53-independent malignant cancer cells through inhibition of HIF-1 pathway. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 2713-2718.	2.2	13
96	Identification by shape-based virtual screening and evaluation of new tyrosinase inhibitors. PeerJ, 2018, 6, e4206.	2.0	13
97	Studies on Chemical Structure Modification and Structure-Activity Relationship of Derivatives of Gambogic Acid at C(39). Chemistry and Biodiversity, 2012, 9, 1579-1590.	2.1	12
98	Microwave-assisted copper- and palladium-catalyzed sonogashira-type coupling of aryl bromides and iodides with trimethylsilylacetylene. Tetrahedron Letters, 2016, 57, 1100-1103.	1.4	12
99	Discovery, molecular dynamic simulation and biological evaluation of structurally diverse cholinesterase inhibitors with new scaffold through shape-based pharmacophore virtual screening. Bioorganic Chemistry, 2019, 92, 103294.	4.1	12
100	A Mild and Direct C(sp ³) \rightarrow S Cross-Coupling of Oxindoles with Thiols: Synthesis of Unsymmetrical 3-Thiooxindoles. Journal of Organic Chemistry, 2019, 84, 14342-14348.	3.2	12
101	Characterization, quantitation, similarity evaluation and combination with Na ⁺ ,K ⁺ -ATPase of cardiac glycosides from <i>Streblus asper</i> . Bioorganic Chemistry, 2019, 87, 265-275.	4.1	12
102	Design, Synthesis, and Evaluation of Acetylcholinesterase and Butyrylcholinesterase Dual-Target Inhibitors against Alzheimer's Diseases. Molecules, 2020, 25, 489.	3.8	12
103	More than a Leaving Group: <i>N</i> -Phenyltrifluoroacetimidate as a Remote Directing Group for Highly Selective 1,2-cis Glycosylation. Angewandte Chemie - International Edition, 2022, 61, .	13.8	12
104	LYG-202 Augments Tumor Necrosis Factor- α -Induced Apoptosis via Attenuating Casein Kinase 2-Dependent Nuclear Factor- κ B Pathway in HepG2 Cells. Molecular Pharmacology, 2012, 82, 958-971.	2.3	11
105	A facile and efficient [4 + 2] annulation reaction of sulfur ylides: access to N-fused benzimidazoles. Organic Chemistry Frontiers, 2019, 6, 205-208.	4.5	11
106	Alkylsulfonamide-containing quinazoline derivatives as potent and orally bioavailable PI3Ks inhibitors. Bioorganic and Medicinal Chemistry, 2019, 27, 114930.	3.0	11
107	Computational design of binder as the LC3-p62 protein-protein interaction. Bioorganic Chemistry, 2021, 115, 105241.	4.1	11
108	AKR1C3 regulated by NRF2/MAFG complex promotes proliferation via stabilizing PARP1 in hepatocellular carcinoma. Oncogene, 2022, 41, 3846-3858.	5.9	11

#	ARTICLE	IF	CITATIONS
109	Docking Study and Three-Dimensional Quantitative Structure-Activity Relationship (3D-QSAR) Analyses and Novel Molecular Design of a Series of 4-Aminoquinazolines as Inhibitors of Aurora B Kinase. Chinese Journal of Chemistry, 2011, 29, 1785-1799.	4.9	10
110	Structure-Based Pharmacophore Modeling from Multicomplex: a Comprehensive Pharmacophore Generation of Protein Kinase CK2 and Virtual Screening Based on it for Novel Inhibitors. Molecular Informatics, 2011, 30, 579-592.	2.5	9
111	Synthesis and Anti-tumor Evaluation of Novel C-37 Modified Derivatives of Gambogic Acid. Chinese Journal of Chemistry, 2012, 30, 1083-1091.	4.9	9
112	Novel IKK β inhibitors discovery based on the co-crystal structure by using binding-conformation-based and ligand-based method. European Journal of Medicinal Chemistry, 2013, 63, 269-278.	5.5	9
113	Kv1.5 Inhibitors for Treatment of Atrial Fibrillation: A Tradeoff between Selectivity and Non-selectivity. Current Topics in Medicinal Chemistry, 2016, 16, 1843-1854.	2.1	9
114	Direct Synthesis of 2,6-Dideoxy- β -D-Glycosides and β -D-Rhamnosides with a Stereodirecting 2-(Diphenylphosphinoyl)acetyl Group. Angewandte Chemie - International Edition, 2022, 61, .	13.8	9
115	Discovery of NAD(P)H:quinone oxidoreductase 1 (NQO1) inhibitors with novel chemical scaffolds by shape-based virtual screening combined with cascade docking. RSC Advances, 2015, 5, 49471-49479.	3.6	8
116	CPUY201112, a novel synthetic small-molecule compound and inhibitor of heat shock protein Hsp90, induces p53-mediated apoptosis in MCF-7 cells. Scientific Reports, 2016, 6, 19004.	3.3	8
117	Achieving effective and selective CK1 inhibitors through structure modification. Future Medicinal Chemistry, 2021, 13, 505-528.	2.3	8
118	Discovery of novel inhibitors disrupting HIF-1 α /von Hippel-Lindau interaction through shape-based screening and cascade docking. PeerJ, 2016, 4, e2757.	2.0	8
119	Studies on Chemical Structure Modification and Structure-Activity Relationship of Gambogic Acid Derivatives at Carbon(34). Chemistry and Biodiversity, 2012, 9, 2295-2308.	2.1	7
120	Synthesis and antibacterial evaluation of a novel series of 10-hydroxyl ketolide derivatives. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 3452-3457.	2.2	7
121	A convenient cyclopropanation process of oxindoles via bromoethylsulfonium salt. Tetrahedron, 2018, 74, 6809-6814.	1.9	7
122	Novel BuChE-IDO1 inhibitors from sertaconazole: Virtual screening, chemical optimization and molecular modeling studies. Bioorganic and Medicinal Chemistry Letters, 2021, 34, 127756.	2.2	7
123	Discovery of Novel Aldo-Keto Reductase 1C3 Inhibitors as Chemotherapeutic Potentiators for Cancer Drug Resistance. ACS Medicinal Chemistry Letters, 2022, 13, 1286-1294.	2.8	7
124	Indenoisoquinoline derivatives as topoisomerase I inhibitors that suppress angiogenesis by affecting the HIF signaling pathway. Biomedicine and Pharmacotherapy, 2013, 67, 715-722.	5.6	6
125	Synthesis and evaluation of a novel class Hsp90 inhibitors containing 1-phenylpiperazine scaffold. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 1557-1561.	2.2	6
126	Identification of novel JMJD2A inhibitor scaffold using shape and electrostatic similarity search combined with docking method and MM-GBSA approach. RSC Advances, 2015, 5, 82936-82946.	3.6	6

#	ARTICLE	IF	CITATIONS
127	Bioorganic and Medicinal Chemistry, 2016, 24, 2423-2432.	3.0	6
128	<i>In silico</i> approaches using pharmacophore model combined with molecular docking for discovery of novel ULK1 inhibitors. Future Medicinal Chemistry, 2021, 13, 341-361.	2.3	6
129	Pharmacophore-Based Drug Design and Biological Evaluation of Novel ABCB1 Inhibitors. Chemical Biology and Drug Design, 2013, 81, 349-358.	3.2	5
130	NbCl ₅ mediated biomimetic cascade reaction: efficient and scalable one-pot synthesis of dunnione and nor- β -lapachone. Tetrahedron Letters, 2015, 56, 397-400.	1.4	5
131	Synthesis and bio-evaluation of a novel selective butyrylcholinesterase inhibitor discovered through structure-based virtual screening. International Journal of Biological Macromolecules, 2021, 166, 1352-1364.	7.5	5
132	Overview of human 20 α -hydroxysteroid dehydrogenase (AKR1C1): Functions, regulation, and structural insights of inhibitors. Chemico-Biological Interactions, 2022, 351, 109746.	4.0	5
133	A Practical and High-Affinity Fluorescent Probe for Butyrylcholinesterase: A Good Strategy for Binding Affinity Characterization. Chinese Journal of Chemistry, 2022, 40, 1285-1292.	4.9	5
134	A highly effective and stable butyrylcholinesterase inhibitor with multi-faceted neuroprotection and cognition improvement. European Journal of Medicinal Chemistry, 2022, 239, 114510.	5.5	5
135	Discovery and Bioevaluation of Novel Pyrazolopyrimidine Analogs as Competitive Hsp90 Inhibitors Through Shape-Based Similarity Screening. Molecular Informatics, 2014, 33, 293-306.	2.5	4
136	Design and evaluation of Nrf2 activators with 1,3,4-oxa/thiadiazole core as neuro-protective agents against oxidative stress in PC-12 cells. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 126853.	2.2	4
137	The Discovery of Novel Histone Lysine Methyltransferase G9a Inhibitors (Part 1): Molecular Design Based on a Series of Substituted 2,4-Diamino-7- aminoalkoxyquinazoline by Molecular-Docking-Guided 3D Quantitative Structure-Activity Relationship Studies. Medicinal Chemistry, 2014, 10, 426-440.	1.5	4
138	Novel Dual-Site Binding Neuraminidase Inhibitor from Virtual Screening by Pharmacophore and Molecular Dynamics Methods. Chinese Journal of Chemistry, 2012, 30, 1735-1740.	4.9	3
139	Convenient Method of Synthesizing Aryloxyalkyl Esters from Phenolic Esters Using Halogenated Alcohols. Molecules, 2018, 23, 1715.	3.8	3
140	Discovery of 2-(cyclopropanecarboxamido)-N-(5-((1-(4-fluorobenzyl)piperidin-4-yl)methoxy)pyridin-3-yl)isonicotinamide as a potent dual AChE/GSK3 β inhibitor for the treatment of Alzheimer's disease: Significantly increasing the level of acetylcholine in the brain without affecting that in intestine. European Journal of Medicinal Chemistry, 2021, 223, 113663.	5.5	3
141	Design, synthesis, biological evaluation and molecular modeling of N-isobutyl-N-((2-(p-tolyloxymethyl)thiazol-4-yl)methyl)benzo[d][1,3] dioxole-5-carboxamides as selective butyrylcholinesterase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2022, 61, 128602.	2.2	3
142	Novel approach to stereoselective synthesis of (E)/(Z)-(N-acyl-oxazolidinone)-eneglycinates. Research on Chemical Intermediates, 2015, 41, 749-760.	2.7	2
143	Betulinic acid acetate, an antiproliferative natural product, suppresses client proteins of heat shock protein pathways through a CDC37-binding mechanism. RSC Advances, 2016, 6, 42537-42544.	3.6	2
144	Discovery of a Selective 6-Hydroxy-1, 4-Diazepan-2-one Containing Butyrylcholinesterase Inhibitor by Virtual Screening and MM-GBSA Rescoring. Dose-Response, 2020, 18, 155932582093852.	1.6	2

#	ARTICLE	IF	CITATIONS
145	Design, Bioevaluation and Molecular Dynamics Simulation of Novel GSK-3 β Inhibitors. <i>Molecular Informatics</i> , 2021, 40, e2060031.	2.5	2
146	Discovery of Novel CK2 Leads by Cross-Docking Based Virtual Screening. <i>Medicinal Chemistry</i> , 2014, 10, 628-639.	1.5	2
147	Discovery of tryptophan-tetrahydroisoquinoline derivatives as multifunctional agents for treatment of Alzheimer's disease. <i>Chinese Journal of Chemistry</i> , 0, , .	4.9	2
148	Hybrids of the Benzofuran Core from Natural Products and the 2,4-dihydroxy-5-cisopropylbenzene Fragment as Potent Hsp90 Inhibitors: Design, Synthesis and Bioevaluation. <i>Molecular Informatics</i> , 2014, 33, 495-502.	2.5	1
149	Synthesis and activity of miconazole derivatives as dual BChE/IDO1 inhibitors for the treatment of Alzheimer's disease. <i>Future Medicinal Chemistry</i> , 2021, 13, 1105-1125.	2.3	1
150	Insights into Targeting NEMO for Pharmacological Regulation. <i>Current Drug Targets</i> , 2014, 15, 874-887.	2.1	1
151	Synthesis and Bioevaluation of Gambogic Acid Derivatives as Antitumor Agents. <i>Chinese Journal of Organic Chemistry</i> , 2012, 32, 1450.	1.3	1
152	The Design and Optimization of Monomeric Multitarget Peptides for the Treatment of Multifactorial Diseases. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 3685-3705.	6.4	1
153	More than a Leaving Group: <i>N</i> -Phenyltrifluoroacetimidate as a Remote Directing Group for Highly Selective 1,2-cis Glycosylation. <i>Angewandte Chemie</i> , 0, , .	2.0	1
154	Pharmacophore Modeling and in Silico Screening Studies to Design Potential KDR Kinase Inhibitors. <i>Chinese Journal of Chemistry</i> , 2011, 29, 1107-1113.	4.9	0
155	Discovery of Aroyl Piperazine Derivatives as K^+ and K_s Dual Inhibitors for Cardiac Arrhythmia Treatment. <i>Medicinal Chemistry</i> , 2014, 10, 497-505.	1.5	0
156	Elucidating the Novel Mechanism of Ligustrazine in Preventing Postoperative Peritoneal Adhesion Formation. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 2022, 1-30.	4.0	0